In vitro antifungal susceptibility of oral candida species from Iranian HIV infected patients

Tehran University Medical Journal

Volumn 70, Issue 2, 2012, Pages 96-103

  Katiraee, Farzad ^a   Khosravi, Ali Reza ^b   Khalaj, Vahid ^c   Hajiabdolbaghi, Mahbobeh ^d   Khaksar, Ali Asghar ^c   Rasoulinejad, Mehrnaz ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antifungal drug resistance; Azoles; Candida species; HIV infections; Oral candidiasis; Patients

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; NYSTATIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; DISK DIFFUSION; HUMAN; MOUTH FLORA; NONHUMAN;

EID: 84859707580     PISSN: 16831764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol 2000;38(4):1563-8.
2. M. Bharathi and A. Usha Rani. Pathogenic fungal isolates in sputum of HIV positive patients. Journal of AIDS and HIV Research, June 2011, Vol. 3(6), pp. 107-113.
3. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005;7(6):429-39.
4. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis 2004;10(1):14-9.
5. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46(6):1704-13.
6. Espinel-Ingroff A, Barchiesi F, Hazen KC, Martinez-Suarez JV, Scalise G. Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol 1998;36 Suppl 1:68-78. Erratum in: Med Mycol 1999;37(2):147.
7. Pfaller MA, Dupont B, Kobayashi GS, Müller J, Rinaldi MG, Espinel-Ingroff A, et al. Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother 1992;36(9):1805-9.
8. Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996;34(9):2154-7.
9. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003;41(5):1875-80.
10. P. Saravana Bhavan, Culture and Identification of Candida Albicans from Vaginal Ulcer and Separation of Enolase on SDSPAGE, International Journal of Biology 2010, Vol 2 No10 p: 84-93
11. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994;32:1923-9.
12. Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G, Fadda G, et al. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 2007;45(4):1343-6.
13. Odds FC, Davidson A. "Room temperature" use of CHROMagar Candida. Diagn Microbiol Infect Dis 2000;38(3):147-50.
14. Wayne P. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A. National Committee for Clinical Laboratory Standards, 2004
15. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003;41(12):5623-32.
16. Wayne P. National Committee for Clinical Laboratory Standards. Reference method for broth dilution testing of yeasts. Approved standard. 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, 2002
17. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24(2):235-47.
18. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003;47(5):1647-51.
19. Katiraee F, Khosravi AR, Khalaj V, Hajiabdolbaghi M, Khaksar AA, Rasoulinjad M. Oral candidiasis in Human Immunodeficiency Virus (HIV) infected individuals in Iran. Tehran Univ Med J (TUMJ);68(1):37-44.
20. Repentigny LD, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004;17(4):729-59.
21. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002;44(2):169-74.
22. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, et al. Fluconazole resistant opportunistic oropharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008;8(3):142-8.
23. Lyon JP, Moreira LM, Cardoso MAG, Saade J, Resende MA. Antifungal susceptibility profile of Candida spp. oral isolates obtained from denture wearers. Brazil J Microbiol 2008;39:668-72.
24. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIVseronegative women. J Infect Dis 2001;183(2):286-93.
25. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32(9):2092-8.
26. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007;56(Pt 2):255-9.
27. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84(5):826-32.
28. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular identification and in-vitro susceptibility of Candida albicans and C. dubliniensis isolated from immunocompromised patients. Iran Red Crescent Med J 2009;11(4):391-7.
29. Lewis RE, Klepser ME, Pfaller MA. Update on clinical antifungal susceptibility testing for Candida species. Pharmacotherapy 1998;18(3):509-15.
30. Haberland-Carrodeguas C, Allen CM, Beck FM, Buesching WJ, Koletar SL, Sundstrom P. Prevalence of fluconazole-resistant strains of Candida albicans in otherwise healthy outpatients. J Oral Pathol Med 2002;31(2):99-105.
31. Rubio Calvo MC, Gil J, Ramírez de Ocáriz I, Benito R, Rezusta A. In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp. Rev Esp Quimioter 2003;16(2):227-32.
32. Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ. The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J Bacteriol 1996;178(18):5353-60.